fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Adapalene & benzoyl peroxide

All strengths: Off-Formulary Interchangeable, not an ODB benefit; same patient cost rules

Shared coverage and patient cost rules
StatusOff-Formulary Interchangeable, not an ODB benefit
Patient paysNot paid by ODB 65 and over; see alternatives

Sandoz Adapalene/ Benzoyl Peroxide · DIN 02489007 · 0.1 %w/w & 2.5 %w/w · Top Gel

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
1 brand, same coverage
Sandoz Adapalene/ Benzoyl Peroxide · DIN 02489007 Manufacturer: Sandoz Canada Inc.; listing date 2019-11-29 Health Canada: Marketed since 2021-06-21 · brand SANDOZ ADAPALENE / BENZOYL PEROXIDE · ATC D10AD53 ADAPALENE, COMBINATIONS, D10AD53 ADAPALENE, COMBINATIONS · form Gel · route Topical · ingredients BENZOYL PEROXIDE 2.5 %/W/W, ADAPALENE 0.1 %/W/W · company Sandoz canada incorporated · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02489007)

Source record
DIN 02489007: Sandoz Adapalene/ Benzoyl Peroxide Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 842800058; group id 852; item number 2070; lccId None; manufacturer id SDZ Source form: Top Gel; strength: 0.1%w/w & 2.5%w/w Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $1.2718; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02489007 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97906
Interchangeable products
TactuPump · DIN 02365871 · not recorded Taro-Adapalene/Benzoyl Peroxide · DIN 02456923 · not recorded
Shortage status: resolved shortage (ended September 8, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02489007
Shortage record checked October 6, 2026

TactuPump · DIN 02365871 · 0.1 %w/w & 2.5 %w/w · Top Gel

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
Savings card: innoviCares lists TactuPump (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
TactuPump · DIN 02365871 Manufacturer: Galderma Canada Inc; listing date 2019-11-29 Health Canada: Marketed since 2014-06-02 · brand TACTUPUMP · ATC D10AD53 ADAPALENE, COMBINATIONS, D10AD53 ADAPALENE, COMBINATIONS · form Gel · route Topical · ingredients BENZOYL PEROXIDE 2.5 %/W/W, ADAPALENE 0.1 %/W/W · company Galderma canada inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

TactuPump: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02365871)

Source record
DIN 02365871: TactuPump Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 842800058; group id 852; item number 2070; lccId None; manufacturer id GAC Source form: Top Gel; strength: 0.1%w/w & 2.5%w/w Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02365871 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85075
Interchangeable products
Sandoz Adapalene/ Benzoyl Peroxide · DIN 02489007 · not recorded Taro-Adapalene/Benzoyl Peroxide · DIN 02456923 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02365871
Shortage record checked October 6, 2026

Taro-Adapalene/Benzoyl Peroxide · DIN 02456923 · 0.1 %w/w & 2.5 %w/w · Top Gel

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
1 brand, same coverage
Taro-Adapalene/Benzoyl Peroxide · DIN 02456923 Manufacturer: Taro Pharmaceuticals Inc.; listing date 2019-11-29 Health Canada: Marketed since 2019-10-01 · brand TARO-ADAPALENE/BENZOYL PEROXIDE · ATC D10AD53 ADAPALENE, COMBINATIONS, D10AD53 ADAPALENE, COMBINATIONS · form Gel · route Topical · ingredients BENZOYL PEROXIDE 2.5 %/W/W, ADAPALENE 0.1 %/W/W · company Taro pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02456923)

Source record
DIN 02456923: Taro-Adapalene/Benzoyl Peroxide Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 842800058; group id 852; item number 2070; lccId None; manufacturer id TAR Source form: Top Gel; strength: 0.1%w/w & 2.5%w/w Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $1.2719; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02456923 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94404
Interchangeable products
Sandoz Adapalene/ Benzoyl Peroxide · DIN 02489007 · not recorded TactuPump · DIN 02365871 · not recorded
Shortage status: resolved shortage (ended August 5, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02456923
Shortage record checked October 6, 2026

Sandoz Adapalene/Benzoyl Peroxide · DIN 02517205 · 0.3% w/w & 2.5% w/w · Top Gel

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
1 brand, same coverage
Sandoz Adapalene/Benzoyl Peroxide · DIN 02517205 Manufacturer: Sandoz Canada Inc.; listing date 2022-01-31 Health Canada: Marketed since 2022-01-26 · brand SANDOZ ADAPALENE / BENZOYL PEROXIDE FORTE · ATC D10AD53 ADAPALENE, COMBINATIONS, D10AD53 ADAPALENE, COMBINATIONS · form Gel · route Topical · ingredients BENZOYL PEROXIDE 2.5 %/W/W, ADAPALENE 0.3 %/W/W · company Sandoz canada incorporated · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02517205)

Source record
DIN 02517205: Sandoz Adapalene/Benzoyl Peroxide Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 843600106; group id 855; item number 2075; lccId None; manufacturer id SDZ Source form: Top Gel; strength: 0.3% w/w & 2.5% w/w Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $2.1576; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02517205 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100638
Interchangeable products
TactuPump Forte · DIN 02446235 · not recorded Taro-Adapalene/Benzoyl Peroxide Forte · DIN 02505053 · not recorded
Shortage status: resolved shortage (ended November 18, 2024); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02517205
Shortage record checked October 6, 2026

TactuPump Forte · DIN 02446235 · 0.3% w/w & 2.5% w/w · Top Gel

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
Savings card: innoviCares lists TactuPump Forte (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
TactuPump Forte · DIN 02446235 Manufacturer: Galderma Canada Inc; listing date 2022-01-31 Health Canada: Marketed since 2016-01-04 · brand TACTUPUMP FORTE · ATC D10AD53 ADAPALENE, COMBINATIONS, D10AD53 ADAPALENE, COMBINATIONS · form Gel · route Topical · ingredients ADAPALENE 0.3 %/W/W, BENZOYL PEROXIDE 2.5 %/W/W · company Galderma canada inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

TactuPump Forte: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02446235)

Source record
DIN 02446235: TactuPump Forte Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 843600106; group id 855; item number 2075; lccId None; manufacturer id GAC Source form: Top Gel; strength: 0.3% w/w & 2.5% w/w Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02446235 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93152
Interchangeable products
Sandoz Adapalene/Benzoyl Peroxide · DIN 02517205 · not recorded Taro-Adapalene/Benzoyl Peroxide Forte · DIN 02505053 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02446235
Shortage record checked October 6, 2026

Taro-Adapalene/Benzoyl Peroxide Forte · DIN 02505053 · 0.3% w/w & 2.5% w/w · Top Gel

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
1 brand, same coverage
Taro-Adapalene/Benzoyl Peroxide Forte · DIN 02505053 Manufacturer: Taro Pharmaceuticals Inc.; listing date 2022-02-28 Health Canada: Marketed since 2022-01-24 · brand TARO-ADAPALENE/BENZOYL PEROXIDE FORTE · ATC D10AD53 ADAPALENE, COMBINATIONS, D10AD53 ADAPALENE, COMBINATIONS · form Gel · route Topical · ingredients ADAPALENE 0.3 %/W/W, BENZOYL PEROXIDE 2.5 %/W/W · company Taro pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02505053)

Source record
DIN 02505053: Taro-Adapalene/Benzoyl Peroxide Forte Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 843600106; group id 855; item number 2075; lccId None; manufacturer id TAR Source form: Top Gel; strength: 0.3% w/w & 2.5% w/w Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $2.1577; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02505053 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99442
Interchangeable products
Sandoz Adapalene/Benzoyl Peroxide · DIN 02517205 · not recorded TactuPump Forte · DIN 02446235 · not recorded
Shortage status: resolved shortage (ended February 12, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02505053
Shortage record checked October 6, 2026

Other products in the same Health Canada class (D10A, D10AD): coverage varies; not interchangeable

  • Tretinoin (Vitamin A Acid): limited Use 269
  • Azelaic acid (Finacea): general benefit
  • Benzoyl peroxide + clindamycin (Clindoxyl): general benefit
  • Clindamycin (Dalacin T 1%): not a benefit

Clindamycin phosphate & adapalene & benzoyl peroxide

All products: Limited Use (codes 724)

Cabtreo · DIN 02550423 · 1.2% w/w & 0.15% w/w & 3.1% w/w · Top Gel Pump

Limited Use, Reason for Use code 724 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 724 required
Write on scriptReason for Use code 724 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 724
Reason for Use code 724 For the treatment of acne vulgaris in patients 12 years of age and older. Coverage limit: LU Authorization Period: 1 year
No interchangeable product listed in the Ontario extract
Cabtreo · DIN 02550423 Manufacturer: Bausch Health Canada Inc.; listing date 2025-06-30 Health Canada: Marketed since 2024-10-07 · brand CABTREO · ATC D10AF51 CLINDAMYCIN, COMBINATIONS · form Gel · route Topical · ingredients ADAPALENE 0.15 %/W/W, BENZOYL PEROXIDE 3.1 %/W/W, CLINDAMYCIN PHOSPHATE 1.2 %/W/W · company Bausch health, canada inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Cabtreo: Formulary list price $3.01 per unit (the source does not state the unit; exact figure $3.0074). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02550423)

Source record
DIN 02550423: Cabtreo Raw flags: sec12=Y, sec3=Y Item: 840404031; group id 810; item number 1988; lccId 00411; manufacturer id BHC Source form: Top Gel Pump; strength: 1.2% w/w & 0.15% w/w & 3.1% w/w Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $3.0074; ministry $3.0074 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02550423 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103924
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02550423
Shortage record checked October 6, 2026

Other products in the same Health Canada class (D10A, D10AD): coverage varies; not interchangeable

  • Tretinoin (Vitamin A Acid): limited Use 269
  • Azelaic acid (Finacea): general benefit
  • Benzoyl peroxide + clindamycin (Clindoxyl): general benefit
  • Clindamycin (Dalacin T 1%): not a benefit
Other drugs in the same formulary classes and how they are covered

Other drugs in the same formulary class (84:04:04 Antibiotics) and how they are covered

Matched class: 84:04:04 Antibiotics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: CLINDAMYCIN PHOSPHATE & BENZOYL PEROXIDE, FUSIDIC ACID, MUPIROCIN CALCIUM, SODIUM FUSIDATE Some products covered without a code (check the product listing): MUPIROCIN 84:04:04 Antibiotics

CLINDAMYCIN PHOSPHATE & BENZOYL PEROXIDE

· 4 products · General benefit · strengths: 1% & 5% · Gel, Top Gel

CLINDAMYCIN

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1% · Top Sol

FUSIDIC ACID

· 2 products · General benefit · strengths: 2% · Cr

MUPIROCIN

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 2% · Oint

MUPIROCIN CALCIUM

· 1 products · General benefit · strengths: 2% w/w · Cr

SODIUM FUSIDATE

· 2 products · General benefit · strengths: 2% · Oint Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 84:04:04
Full class listing Related classes: 84:04:08 Fungicides, 84:04:12 Parasiticides, 84:04:16 Other Anti-Infectives

Other drugs in the same formulary class (84:28 Keratolytic Agents) and how they are covered

Matched class: 84:28 Keratolytic Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over No displayed product is listed as a general benefit in this extract. Check its listing requirements below. 84:28 Keratolytic Agents

TRETINOIN

· 2 products · Limited Use, codes 269 · strengths: 0.01%, 0.05% · Gel Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 84:28
Full class listing Related classes: 84:04 Anti-Infectives, 84:06 Anti-Inflammatory, 84:36 Miscellaneous Skin and Mucous Membrane Agents

Other drugs in the same formulary class (84:36 Miscellaneous Skin and Mucous Membrane Agents) and how they are covered

Matched class: 84:36 Miscellaneous Skin and Mucous Membrane Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: ACITRETIN, AZELAIC ACID, FLUOROURACIL, ISOTRETINOIN, ZINC SULFATE Some products covered without a code (check the product listing): COLLAGENASE 84:36 Miscellaneous Skin and Mucous Membrane Agents

AZELAIC ACID

· 1 products · General benefit · strengths: 15% · Top Gel

ACITRETIN

· 6 products · General benefit · strengths: 10mg, 25mg · Cap

COLLAGENASE

· 2 products · General benefit (1), Temporary benefit (1) · strengths: 250Unit/g · 30g Pk, Oint-30g Pk

FLUOROURACIL

· 1 products · General benefit · strengths: 5% · Cr

ISOTRETINOIN

· 8 products · General benefit · strengths: 10mg, 20mg, 30mg, 40mg · Cap

ZINC SULFATE

· 2 products · General benefit · strengths: 0.5%, 10mg · Oint, Sup

ALITRETINOIN

· 4 products · Listed, not a benefit (2), Limited Use, codes 442 (2) · strengths: 10mg, 30mg · Cap

BRODALUMAB

· 1 products · Limited Use, codes 553 · strengths: 210mg/1.5mL · Inj Sol-Pref Syr

CALCIPOTRIOL

· 1 products · Limited Use, codes 191 · strengths: 50mcg/g · Oint

CALCITRIOL

· 1 products · Limited Use, codes 191 · strengths: 3mcg/g · Oint

IXEKIZUMAB

· 2 products · Limited Use, codes 526 · strengths: 80mg/mL · Inj Sol-Pref Autoinj, Inj Sol-Pref Syr

PIMECROLIMUS

· 1 products · Limited Use, codes 383 · strengths: 1% · Cr Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 84:36 and 3 more
Full class listing Related classes: 84:04 Anti-Infectives, 84:06 Anti-Inflammatory, 84:28 Keratolytic Agents Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: acne
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. CLINDAMYCIN · Off-Formulary Interchangeable, not an ODB benefit INDICATIONS AND CLINICAL USE Taro-Clindamycin 1% (clindamycin phosphate) is indicated for the treatment of acne vulgaris. PM: https://pdf.hres.ca/dpd_pm/00058691.PDF; date not captured; DIN 02266938; fetched 2026-09-10 Product monograph TAZAROTENE · Limited Use, codes 636 1 INDICATIONS ARAZLO™ (tazarotene lotion), is indicated for: • For the topical treatment of acne vulgaris in patients 10 years of age and older. 1.1 Pediatrics Pediatrics (≥ 10 years of age) The safety and efficacy of ARAZLO in pediatric patients (10 years of age and older) has been established. PM: https://pdf.hres.ca/dpd_pm/00082613.PDF; date NOV 28, 2025; DIN 02517868; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-09-22
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE TACTUPUMP (adapalene 0.1%/benzoyl peroxide 2.5%) Topical Gel is indicated for:  Treatment of mild and moderate acne vulgaris, characterized by comedones, inflammatory papules/ pustules in patients 9 years of age and older. TACTUPUMP FORTE (adapalene 0.3%/benzoyl peroxide 2.5%) Topical Gel is indicated for:  Treatment of moderate and severe acne vulgaris, characterized by comedones, inflammatory papules/pustules with or without occasional nodules in patients 12 years of age and older. CLINICAL USE Physicians should be able to choose between the two concentrations TACTUPUMP FORTE Topical Gel and TACTUPUMP Topical Gel based on the presenting patient’s clinical condition and confounding factors that could worsen acne severity. TACTUPUMP / TACTUPUMP FORTE Product Monograph Page 3 of 43 TACTUPUMP FORTE may also be considered for those patients who have moderate and severe acne vulgaris, who may have risk factors that worsen acne prognosis such as tendency toward cyclical relapses, pre-pubertal onset or long term history of acne, positive family / genetic history, those prone to … https://pdf.hres.ca/dpd_pm/00051234.PDF PM date: May 17, 2019 Source product: TACTUPUMP; DIN 02365871; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 INDICATIONS CABTREO (clindamycin phosphate, adapalene and benzoyl peroxide) is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older. CABTREO contains an antibacterial ingredient, clindamycin. To reduce the risk of development of drug-resistant bacteria and maintain the effectiveness of clindamycin, CABTREO should only be used for the authorized indication and clinical use. 1.1 Pediatrics Pediatrics (< 12 years of age): The safety and efficacy of CABTREO in pediatric patients (12 years of age and older) have been established; therefore, Health Canada has authorized an indication for pediatric patients (see 7.1.3 Pediatrics). 1.2 Geriatrics Geriatrics (> 65 years of age): A limited number of subjects aged ≥ 65 years have been treated with CABTREO in clinical trials; therefore, the safety and efficacy of CABTREO have not been established in this patient population (see 7.1.4 Geriatrics). https://pdf.hres.ca/dpd_pm/00076715.PDF PM date: AUG 14, 2024 Source product: CABTREO; DIN 02550423; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18

Other review policies

For Sandoz Adapalene/ Benzoyl Peroxide, TactuPump, Taro-Adapalene/Benzoyl Peroxide, Sandoz Adapalene/Benzoyl Peroxide, TactuPump Forte, Taro-Adapalene/Benzoyl Peroxide Forte: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026